Company news
Humanwell Healthcare (group) Co.,ltd. Class A (SSE:600079) news
Humanwell Healthcare (group) Co.,ltd. Class A news releases on 6ix. Latest, Dec 13, 2025: Announcement on Receiving the Notice in Advance of Administrative…
Press releases — page 2
Announcement on Receiving the Notice in Advance of Administrative Penalty from Hubei Securities Regulatory Bureau of China Securities Regulatory Commission
December 12, 2025
Announcement on Obtaining Marketing Authorization from the German Federal Institute for Drugs and Medical Devices (BfArM) for Midazolam Injection
December 11, 2025
Announcement on Resolutions of the 4th Meeting of the 11th Board of Directors
December 5, 2025
Announcement on Withdrawal of Drug Registration Application by Subsidiary
December 2, 2025
Announcement on Participation in Investment for Establishing Private Equity Fund and Related Party Transaction
November 28, 2025
Announcement on Initiation of Phase II Clinical Trial for HW231019 Tablets
November 12, 2025
Announcement on Pledge of Partial Shares of Controlling Shareholder
November 7, 2025
Announcement on HWH217 Tablets Obtaining Notice of Approval for Drug Clinical Trials
November 6, 2025
Announcement on Pregabalin Sustained Release Tablets Obtaining Notice of Approval for Drug Clinical Trials
November 3, 2025
Announcement on the Fulfillment of Commitments by Shareholders Holding More Than 5% Shares
October 30, 2025
Announcement on Resolutions of the 3rd Meeting of the 11th Board of Directors
October 29, 2025
Announcement on Progress in Signing of "Financial Services Agreement" and Related Party Transactions
October 13, 2025
Announcement on Temporary Approval Number Granted by the US FDA for Oxcitabine Sustained-release Tablets
September 19, 2025
Announcement on Obtaining Drug Registration Certificate for Levonorgestrel Tablets
September 16, 2025
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025
September 12, 2025
Announcement on Jade Silkworm Granules Entering Phase 2 Clinical Trial Study
September 9, 2025
Announcement on Obtaining Drug Registration Certificate for Icosapent Ethyl Soft Capsules
September 2, 2025
Indicative Announcement on Equity Change of Controlling Shareholder and Its Persons Acting in Concert Reaching 1%
September 1, 2025
Announcement on Renewing Engagement of Accounting Firm
August 27, 2025
Announcement on Obtaining Drug Registration Certificate for Remimazolam Besylate for Injection with Increased Indications
August 25, 2025
Announcement on Implementation of Dividend Distribution for 2024
August 11, 2025
Announcement on HW241045 Tablets Obtaining Notice of Approval for Drug Clinical Trials
August 5, 2025
Announcement on Approval of Drug Registration Certificate for Drospirenone and Ethinylestradiol Tablets
July 31, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
July 30, 2025
Announcement on Obtaining Drug Registration Certificate for Rivastigmine Transdermal Patch
July 22, 2025
Announcement on Adding Extraordinary Proposal to the 3rd Extraordinary General Meeting in 2025
July 18, 2025
Humanwell Healthcare : >Humanwell PuraCap Pharmaceutical LLC Announces Successful FDA Inspection
November 11, 2015